Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 9, 2013 - Issue 12
Submit an article Journal homepage
111
Views
17
CrossRef citations to date
0
Altmetric
Special Reports

Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase

Frans K GorusDiabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, BelgiumCorrespondence[email protected]
,
Bart KeymeulenDiabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
,
Peter A In’t VeldDiabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
&
Daniel G PipeleersDiabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
Pages 1173-1183 | Published online: 10 Jan 2014

References

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 36( Suppl. 1), S67–S74 (2013).
  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).
  • Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005-20: a multicenter prospective registration study. Lancet 376, 259–266 (2009).
  • Weets I, De Leeuw I, Du Caju M et al.; Belgian Diabetes Registry. The incidence of type 1 diabetes in the age group 0–39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 25, 840–846 (2002).
  • Pipeleers D, Chintinne M, Denys B, Martens G, Keymeulen B, Gorus F. Restoring a functional beta cell mass in diabetes. Diabetes Obes. Metab. 10( Suppl. 4), 54–62 (2008).
  • Gorus F, Pipeleers D; Belgian Diabetes Registry. Prospects for predicting and stopping the development of type 1 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 15, 371–389 (2001).
  • Brooks-Worrell B, Palmer JP. Prevention versus intervention of type 1 diabetes. Clin. Immunol. doi:10.1016/j.clim.2013.05.018 (2013) ( Epub ahead of print).
  • Skyler JS. Primary and secondary prevention in type 1 diabetes. Diabet. Med. 30, 161–169 (2013).
  • Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes. Diabetologia 49, 261–270 (2006).
  • Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology and therapeutic strategies. Physiol. Rev. 91, 79–119 (2011).
  • Keymeulen B, Vandemeulebroucke E, Ziegler A et al. Insulin needs following CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).
  • Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab. Rev. 8, 209–227 (1992).
  • Leslie RD, Delli Castelli M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53, 3033–3040 (2004).
  • Knip M, Virtanen SM, Seppä K et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N. Engl. J. Med. 363, 1900–1908 (2010).
  • Diabetes Prevention Trial — Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685–1691 (2002).
  • Vandemeulebroucke E, Gorus F, Decochez K et al.; Belgian Diabetes Registry. Insulin treatment in IA-2 antibody positive relatives of type 1 diabetic patients. Diabetes Metab. 35, 319–327 (2009).
  • The ENDIT group. Intervening before the onset of type 1 diabetes: results of the european Nicotinamide diabetes intervention trial (ENDIT). Lancet 363, 925–931 (2004).
  • Näntö-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double blind, randomized controlled trial. Lancet 372, 1746–1755 (2008).
  • Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 60 1–8 (2011).
  • Bach JF, Chatenoud L. A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Sem. Immunol. 23, 174–181 (2011).
  • Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002).
  • Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion and preservation of beta cell function. N. Engl. J. Med. 361, 2143–2152 (2009).
  • Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial. Lancet 378, 412–419 (2011).
  • Ludvigsson J, Faresjö M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909–1920 (2008).
  • Raz I, Elias D, Avron A, Tamin M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep 277): a randomized, double-blind, phase II trial. Lancet 358, 1749–1753 (2001).
  • Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomized controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53, 614–623 (2010).
  • Keymeulen B, Gillard P, Mathieu C et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell grafts. Proc. Natl Acad. Sci. USA 103, 17444–17449 (2006).
  • In ‘t Veld P. Insulitis in human type 1 diabetes. Islets 3, 131–138 (2011).
  • Gorus FK. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab. Rev. 13, 247–274 (1997).
  • Van der Auwera B, Van Autreve J, Schuit F, Weets I, Ivens A, Gorus F; Belgian Diabetes Registry. Relative and absolute HLA DQA1-DQB1-linked risk for developing type 1 diabetes before age 40 years in the Belgian population: implications for future prevention studies. Hum. Immunol. 63, 40–50 (2002).
  • Vandewalle C, Coeckelberghs M, De Leeuw I et al. Epidemiology, clinical aspects and biology of IDDM under age 40 years. Comparison of data from Antwerp with complete ascertainment with those from Belgium with 40 % ascertainment. Diabetes Care 20, 1556–1561 (1997).
  • Vandemeulebroucke E, Keymeulen B, Decochez K et al.; Belgian Diabetes Registry. Hyperglycaemic clamp test for diabetes risk assessment in IA-2 antibody positive relatives of type 1 diabetic patients. Diabetologia 53, 36–44 (2010).
  • Campbell-Thompson ML, Atkinson MA, Butler AF. The diagnosis of insulitis in human type 1 diabetes. Diabetologia 56, 2541–2543 (2013).
  • Elding Larsson H, Vehik K, Bell R et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 34, 2347–2352 (2011).
  • Mahon JL, Dupré J. The limitations of clinical trials for prevention of IDDM. Diabetes Care 20, 1027–1033 (1997).
  • Robertson RP. Estimation of ß-cell mass by metabolic tests. Necessary, but how efficient? Diabetes 56, 2420–2424 (2007).
  • Bingley PJ, Bonifacio E, Gale EA. Can we really predict IDDM? Diabetes 42, 213–220 (1993).
  • De Grijse J, Asanghanwa M, Nouthé B et al.; Belgian Diabetes Registry. Predictive power of screening for antibodies against IA-2(beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 53, 517–524 (2010).
  • Gorus F, Balti E, Vermeulen I et al.; Belgian Diabetes Registry. Screening for IA-2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset. Clin. Exp. Immunol. 171, 82–90 (2013).
  • Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. Lancet 378, 487–497 (2011).
  • Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222, 1337–1339 (1983).
  • Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347, 151–156 (1990).
  • Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc. Natl Acad. Sci. USA 93, 6367–6370 (1996).
  • Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc 30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl Acad. Sci. USA 104, 17040–17045 (2007).
  • Verge CF, Gianani R, Kawasaki E et al. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45, 926–933 (1996).
  • Yu L, Rewers M, Gianini R et al. Anti islet autoantibodies usually develop sequentially rather than simultaneously. J. Clin. Endocrinol. Metab. 81, 4264–4267 (1996).
  • Vermeulen I, Weets I, Costa O et al.; Belgian Diabetes Registry. An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent antibody-positivity after age 10. Diabetologia 55, 413–420 (2012).
  • Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of diabetes. Diabetes 54( Suppl. 2), S25–S31 (2005).
  • Pihoker C, Gilliam LK, Hampe CS, Lernmark Á. Autoantibodies in diabetes. Diabetes 54( Suppl. 2), S52–S61 (2005).
  • Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 32, 468–478 (2010).
  • Decochez K, De Leeuw IH, Keymeulen B et al.; Belgian Diabetes Registry. IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients. Diabetologia 45, 1658–1666 (2002).
  • Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk to progression to diabetes in children. JAMA 309, 2473–2479 (2013).
  • Todd JA. Etiology of type 1 diabetes. Immunity 32, 457–467 (2010).
  • Decochez K, Truyen I, Van der Auwera B et al.; Belgian Diabetes Registry. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 48, 687–694 (2005).
  • Mbunwe E, Van der Auwera B, Vermeulen I et al.; Belgian Diabetes Registry. HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody positive first-degree relatives of type 1 diabetic patients. Diabetes 62, 1345–1350 (2013).
  • Mbunwe E, Van der Auwera B, Weets I et al.; Belgian Diabetes Registry. In autoantibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18 – but not HLA-B*39 – are predictors of impending diabetes with distinct HLA-DQ interactions. Diabetologia 56, 1964–1970 (2013).
  • Baschal EE, Eisenbarth GS. Extreme genetic risk for type 1A diabetes in the post-genome era. J. Autoimmun. 31, 1–6 (2008).
  • Lipponen K, Gombos Z, Kiviniemi M et al. Effect of HLA class I and class II alleles in progression form autoantibody positivity to overt type 1 diabetes in children with risk-associated class II genotypes. Diabetes 59, 3253–3256 (2010).
  • Erlich HA, Valdes AM, Noble J. Prediction of type 1 diabetes. Diabetes 62, 1020–2021 (2013).
  • Steck AK, Wong R, Wagner B et al. Effects of non-HLA gene polymorphisms or development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR, DQ genotypes. Diabetes 61, 753–758 (2012).
  • Winkler C, Krumsich J, Lempainen J et al. A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes Immun. 13, 549–555 (2012).
  • Lempainen J, Hermann R, Veijola R, Simell O, Knip M, Ilonen J. Effect of PTPN22 and INS risk genotypes on the progression to clinical type 1 diabetes after initiation of ß-cell autoimmunity. Diabetes 61, 963–966 (2012).
  • Achenbach P, Hummel M, Thümer L, Boerschmann H, Höfelmann D, Ziegler AG. Characteristics of rapid vs. slow progression to type 1 diabetes in multiple autoantibody-positive children. Diabetologia 56, 1615–1622 (2013).
  • Pugliese A, Gianani R, Moromisato R et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody positive first-degree relatives of patients with IDDM. Diabetes 44, 608–613 (1995).
  • Van der Auwera B, Van Waeyenberge C, Schuit F et al.; Belgian Diabetes Registry. DRB1*0403 protects against IDDM in Caucasians with the high risk heterozygous DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 genotype. Diabetes 44, 527–530 (1995).
  • Truyen I, De Pauw P, Jørgensen P et al.; Belgian Diabetes Registry. Proinsulin level and proinsulin-to-C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 48, 2322–2329 (2005).
  • Krischer JP; Type 1 Diabetes Trial Net Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 56, 1919–1924 (2013).
  • Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS. Pre-type 1 diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes 33, 717–720 (1984).
  • Smith CP, Tarn AC, Thomas JM et al. Between and within subject variation of the first phase insulin response to intravenous glucose. Diabetologia 31, 123–125 (1988).
  • Xu P, Beam CA, Cuthberson D, Sosenko JM, Skyler JS, Krischer JP; DPT-1 Study Group. Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 35, 1975–1980 (2012).
  • Greenbaum CJ, Mandrup-Poulson T, Mc Gee PF et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966–1971 (2008).
  • De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214–E223 (1979).
  • Røder ME, Knip M, Hartling SG, Karjalainen J, Ákerblom HK, Binder C. Disproportionally elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first-phase insulin responses. The Childhood Diabetes in Finland Study Group. J. Clin. Endocrinol. Metab. 79, 1570–1575 (1994).
  • Røder ME, Porte DJ, Schwartz RS, Kahn SE. Disproportionally elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 83, 604–608 (1998).
  • Hostens K, Ling Z, Van Schravendijk C, Pipeleers DG. Prolonged exposure of human beta cells to high glucose increased their release of proinsulin during acute stimulation with glucose or arginine. J. Clin. Endocrino.l Metab. 84, 1386–1390 (1999).
  • Hostens K, Pavolovic D, Zambre Y et al. Exposure of human islets to cytokines can result in disproportionally elevated proinsulin release. J. Clin. Invest. 104, 67–72 (1999).
  • De Pauw P, Vermeulen I, Ubani O et al. Simultaneous determination of plasma concentrations of proinsulin, C-peptide, and their ratio with a trefoil-type time-resolved fluorescence immunoassay. Clin. Chem. 54, 1990–1998 (2008).
  • Lampeter EF, Homberg M, Quabeck K et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 341, 1243–1244 (1993).
  • Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 345, 1036–1040 (2001).
  • Mallone R, Roep BO. Biomarkers for immune intervention trials in type 1 diabetes. Clin. Immunol. doi:10.1016/j.clim.2013.02.009 (2013) ( Epub ahead of print).
  • Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113, 451–463 (2004).
  • Luce S, Lemonnier F, Briand JP et al. Single insulin-specific CD8+ T cells show characteristic gene expression profiles in human type 1 diabetes. Diabetes 60, 3289–3299 (2011).
  • Huurman VA, Hilbrands R, Pinkse GG et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3, e2435 (2008).
  • Hilbrands R, Huurman VA, Gillard P et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 58, 2267–2276 (2009).
  • Fourlanos S, Perry C, Gellert SA et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60, 1237–1245 (2011).
  • Greenbaum CJ, Schatz DA, Haller MJ et al. Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes 61, 1323–1330 (2012).
  • In ’t Veld P, Lievens D, De Grijse J et al. Screening for insulitis in autoantibody-positive non-diabetic organ donors. Diabetes 56, 2400–2404 (2007).
  • Campbell-Thompson M, Wasserfall C, Kaddis J et al. Network for pancreatic organ donors with diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab. Res. Rev. 28(7), 608–617 (2012).
  • Rui M, Hampe C, Wang C et al. Species and epitope specificity of two 65 kDa glutamate decarboxylase time resolved fluorometric immunoassays. J. Immunol. Methods 319, 133–143 (2007).
  • Jiang L, Brackeva B, Ling Z et al. Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic beta cell injury in vitro and in vivo. Diabetes 62, 2683–2688 (2013).
  • Akirav EM, Lebastchi J, Galvan EM et al. Detection of beta cell death in diabetes using differentially methylated circulating DNA. Diabetes 60, 876–883 (2011).
  • Erener S, Mojibian M, Fox JK, Denroche HC, Kieffer TJ. Circulating miR-375 as a biomarker of ß-cell death and diabetes in mice. Endocrinology 154, 603–608 (2013).
  • Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP; DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin. Diabetes Care 34, 1585–1590 (2011).
  • Sosenko JM, Skyler JS, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes 61, 1331–1337 (2012).
  • Skyler JS, Greenbaum CJ, Lachin JM et al.; Type 1 Diabetes TrialNet -- An international collaborative clinical trials network. Ann. NY Acad. Sci. 1150, 14–24 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.